EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis

Cristina Membrive-Jiménez, Cristina Pérez-Ramírez, Salvador Arias-Santiago iD, Antonio Giovanni Richetta, Laura Ottini iD, Laura Elena Pineda-Lancheros iD, Maria Del Carmen Ramírez-Tortosa iD, Alberto Jiménez-Morales

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24108703 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Cristina Membrive-Jiménez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacogenetics Unit, Pharmacy Service, University Hospital Virgen de las Nieves, Avenida. de las Fuerzas Armadas 2, 18004 Granada, Spain. Hauptthemen laut MEDLINE: Psoriasis, Organic Anion Transporters. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Granada and the Fundación de Investigación Biosanitaria de Andalucía Oriental (FIBAO), ERDF funds (EU) from the Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biological therapies (BTs) indicated for psoriasis are highly effective; however, not all patients obtain good results, and loss of effectiveness is the main reason for switching. Genetic factors may be involved. The objective of this study was to evaluate the influence of single-nucleotide polymorphisms (SNPs) on the drug survival of tumor necrosis factor inhibitors (anti-TNF) medications and ustekinumab (UTK) in patients diagnosed with moderate-to-severe psoriasis. We conducted an ambispective observational cohort study that included 379 lines of treatment with anti-TNF (n = 247) and UTK (132) in 206 white patients from southern Spain and Italy. The genotyping of the 29 functional SNPs was carried out using real-time polymerase chain reaction (PCR) with TaqMan probes. Drug survival was evaluated with Cox regression and Kaplan–Meier curves. The multivariate analysis showed that the HLA-C rs12191877-T (hazard ratio [HR] = 0.560; 95% CI = 0.40–0.78; p = 0.0006) and TNF-1031 (rs1799964-C) (HR = 0.707; 95% CI = 0.50–0.99; p = 0.048) polymorphisms are associated with anti-TNF drug survival, while TLR5 rs5744174-G (HR = 0.589; 95% CI = 0.37–0.92; p = 0.02), CD84 rs6427528-GG (HR = 0.557; 95% CI = 0.35–0.88; p = 0.013) and PDE3A rs11045392-T together with SLCO1C1 rs3794271-T (HR = 0.508; 95% CI = 0.32–0.79; p = 0.002) are related to UTK survival. The limitations are the sample size and the clustering of anti-TNF drugs; we used a homogeneous cohort of patients from 2 hospitals only. In conclusion, SNPs in the HLA-C, TNF, TLR5, CD84, PDE3A, and SLCO1C1 genes may be useful as biomarkers of drug survival of BTs indicated for psoriasis, making it possible to implement personalized medicine that will reduce financial healthcare costs, facilitate medical decision-making and improve patient quality of life. However, further pharmacogenetic studies need to be conducted to confirm these associations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisOrganic Anion TransportersHumansTumor Necrosis Factor InhibitorsHLA-C AntigensQuality of LifeToll-Like Receptor 5UstekinumabBiological TherapyAdalimumabTumor Necrosis Factor-alphaInfliximabSignaling Lymphocytic Activation Molecule Family

Stichwörter der Autor:innen

CD84HLA-CPDE3ATLR5TNF-1031adalimumabanti-TNFetanerceptinfliximabustekinumab

Substanzen

Tumor Necrosis Factor InhibitorsHLA-C AntigensToll-Like Receptor 5UstekinumabAdalimumabTumor Necrosis Factor-alphaInfliximabCD84 protein, humanSignaling Lymphocytic Activation Molecule FamilySLCO1C1 protein, human

Autor:innen und Institutionen

  • Pharmacogenetics Unit, Pharmacy Service, University Hospital Virgen de las Nieves, Avenida. de las Fuerzas Armadas 2, 18004 Granada, Spain.
  • Department of Biochemistry and Molecular Biology II, Faculty of Pharmacy, Campus Universitario de Cartuja, University of Granada, 18011 Granada, Spain.
  • Dermatology Service, University Hospital Virgen de las Nieves, 18014 Granada, Spain.
  • Unit of Dermatology, Department of Internal Medicine and Medical Specialties Sapienza, University of Rome, 00161 Rome, Italy.
  • Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.

ORCID-Profile: Salvador Arias-Santiago, Laura Ottini, Laura Elena Pineda-Lancheros, Maria Del Carmen Ramírez-Tortosa

Förderung

  • University of Granada and the Fundación de Investigación Biosanitaria de Andalucía Oriental (FIBAO)
  • ERDF funds (EU) from the Instituto de Salud Carlos III

Zitieren

APA

Membrive-Jiménez, C., Pérez-Ramírez, C., Arias-Santiago, S., Richetta, A. G., Ottini, L., Pineda-Lancheros, L. E., Ramírez-Tortosa, M. D. C., & Jiménez-Morales, A. (2023). Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24108703

Vancouver

Membrive-Jiménez C, Pérez-Ramírez C, Arias-Santiago S, Richetta AG, Ottini L, Pineda-Lancheros LE, et al. Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24108703

BibTeX
@article{MembriveJimnez2023,
  author = {Membrive-Jiménez, Cristina and Pérez-Ramírez, Cristina and Arias-Santiago, Salvador and Richetta, Antonio Giovanni and Ottini, Laura and Pineda-Lancheros, Laura Elena and Ramírez-Tortosa, Maria Del Carmen and Jiménez-Morales, Alberto},
  title = {Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24108703}
}
Kostenlos starten →